EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel precision medicine approaches and treatment strategies in hematological malignancies

Richard Rosenquist iD, Elsa Bernard iD, Tom Erkers, David W Scott, Raphael Itzykson, Philippe Rousselot, Jean Soulier, Martin Hutchings, Päivi Östling, Lucia Cavelier, Thoas Fioretos, Karin E Smedby iD

Journal of Internal Medicine · 2023-10 · 294 (4) · 413-436

DOI: 10.1111/joim.13697 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Internal Medicine, online erschienen am 07.08.2023. Verfasst von Richard Rosenquist und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 194 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genetic testing has been applied for decades in clinical routine diagnostics of hematological malignancies to improve disease (sub)classification, prognostication, patient management, and survival. In recent classifications of hematological malignancies, disease subtypes are defined by key recurrent genetic alterations detected by conventional methods (i.e., cytogenetics, fluorescence in situ hybridization, and targeted sequencing). Hematological malignancies were also one of the first disease areas in which targeted therapies were introduced, the prime example being BCR::ABL1 inhibitors, followed by an increasing number of targeted inhibitors hitting the Achilles’ heel of each disease, resulting in a clear patient benefit. Owing to the technical advances in high‐throughput sequencing, we can now apply broad genomic tests, including comprehensive gene panels or whole‐genome and whole‐transcriptome sequencing, to identify clinically important diagnostic, prognostic, and predictive markers. In this review, we give examples of how precision diagnostics has been implemented to guide treatment selection and improve survival in myeloid (myelodysplastic syndromes and acute myeloid leukemia) and lymphoid malignancies (acute lymphoblastic leukemia, diffuse large B‐cell lymphoma, and chronic lymphocytic leukemia). We discuss the relevance and potential of monitoring measurable residual disease using ultra‐sensitive techniques to assess therapy response and detect early relapses. Finally, we bring up the promising avenue of functional precision medicine, combining ex vivo drug screening with various omics technologies, to provide novel treatment options for patients with advanced disease. Although we are only in the beginning of the field of precision hematology, we foresee rapid development with new types of diagnostics and treatment strategies becoming available to the benefit of our patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteHumansPrecision MedicineIn Situ Hybridization, Fluorescence

Stichwörter der Autor:innen

hematological malignanciesmeasurable residual diseaseprecision diagnosticsprecision medicinetargeted therapy

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Clinical Genetics, Karolinska University Hospital, Solna, Stockholm, Sweden.
  • Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, USA.
  • PRISM Center for Personalized Medicine, Gustave Roussy, Villejuif, France.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • SciLifeLab, Stockholm, Sweden.

ORCID-Profile: Richard Rosenquist, Elsa Bernard, Karin E Smedby

Zitieren

APA

Rosenquist, R., Bernard, E., Erkers, T., Scott, D. W., Itzykson, R., Rousselot, P., Soulier, J., Hutchings, M., Östling, P., Cavelier, L., Fioretos, T., & Smedby, K. E. (2023). Novel precision medicine approaches and treatment strategies in hematological malignancies. Journal of Internal Medicine, 294(4), 413-436. https://doi.org/10.1111/joim.13697

Vancouver

Rosenquist R, Bernard E, Erkers T, Scott DW, Itzykson R, Rousselot P, et al. Novel precision medicine approaches and treatment strategies in hematological malignancies. Journal of Internal Medicine. 2023;294(4):413-436. doi:10.1111/joim.13697

BibTeX
@article{Rosenquist2023,
  author = {Rosenquist, Richard and Bernard, Elsa and Erkers, Tom and Scott, David W and Itzykson, Raphael and Rousselot, Philippe and Soulier, Jean and Hutchings, Martin and Östling, Päivi and Cavelier, Lucia and Fioretos, Thoas and Smedby, Karin E},
  title = {Novel precision medicine approaches and treatment strategies in hematological malignancies},
  journal = {Journal of Internal Medicine},
  year = {2023},
  volume = {294},
  number = {4},
  pages = {413--436},
  doi = {10.1111/joim.13697}
}
Kostenlos starten →